- Home
- UAA vs ELVN Comparison
UAA vs ELVN Comparison
Compare UAA & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UAA | ELVN |
|---|---|---|
| Founded | 1996 | 2016 |
| Country | United States | United States |
| Employees | 14100 | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.2B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | UAA | ELVN |
|---|---|---|
| Price | $5.84 | $42.55 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 16 | 5 |
| Target Price | $6.48 | ★ $43.40 |
| AVG Volume (30 Days) | ★ 7.0M | 1.4M |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.17 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.57 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.13 | $14.79 |
| 52 Week High | $8.15 | $48.53 |
Technical Indicators
Market Signals| Indicator | UAA | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 54.09 | 57.92 |
| Support Level | $5.39 | $17.90 |
| Resistance Level | $6.10 | $48.53 |
| Average True Range (ATR) | 0.24 | 3.05 |
| MACD | 0.07 | 0.82 |
| Stochastic Oscillator | 66.07 | 72.16 |
Price Performance
Historical ComparisonAbout UAA Under Armour Inc.
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America, Asia-Pacific, Europe, and Latin America. Consumers of its performance-based clothing and shoes include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through wholesale partners, company-owned digital channels, and approximately 440 company-owned outlet and full-price stores. The Baltimore-based firm was founded in 1996 and is led by controlling shareholder Kevin Plank.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.